Chiyu Ge,
Junli Zhang* and
Feng Feng
School of Pharmacy, Jiangsu Food and Pharmaceutical Science College, Meicheng Road No. 4, Huaian City, Jiangsu Province, P. R. China. E-mail: zhangjunlijl@sina.com
First published on 29th April 2024
Retraction of ‘Salidroside enhances the anti-cancerous effect of imatinib on human acute monocytic leukemia via the induction of autophagy-related apoptosis through AMPK activation’ by Chiyu Ge et al., RSC Adv., 2019, 9, 25022–25033, https://doi.org/10.1039/C9RA01683J.
Many panels in Fig. 2b have been duplicated in other publications by different authors (T. Liu, A. Li, Y. Xu and Y. Xin, Cancer Med., 2019, 8, 751–760; N. Tang, Y. Dong, C. Chen and H. Zhao, Front Pharmacol., 2020, 11, 519172; and Y. Zhang, H. Du, X. Yu and J. Zhu, Ann Transl Med., 2020, 8, 1501).
The ‘Ctrl/Kidney’ panel in Fig. 6c is duplicated in another publication by different authors (Y. Tian, J. Shu, R. Huang, X. Chu and X. Mei, Transl Androl Urol., 2020, 9, 1356–1365).
The ‘Liver/Salidroside + Imatinib’ panel in Fig. 6c is duplicated in another publication by different authors (W. Yan, K. Li, A. Buhe, T. Li, P. Tian and J. Hong, RSC Adv., 2019, 9, 25655–25666).
The authors were asked to provide the raw data for this article, but did not respond. Given the significance of the concerns about the validity of the data, and the lack of raw data, the findings in this paper are not reliable.
The authors have been informed but have not responded to any correspondence regarding the retraction.
Signed: Laura Fisher, Executive Editor, RSC Advances
Date: 17th April 2024
This journal is © The Royal Society of Chemistry 2024 |